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Abstract:  
Purpose: To comprehensively quantify through daily, serial measures changes in knee laxity as  
a function of changing sex-hormone levels across one complete menstrual cycle.  
Methods: Twenty-five females, 18–30 yr, body mass index <= 30, who reported normal 
menstrual cycles (28–32 d) over the past 6 months participated. Participants were tested daily 
across one complete menstrual cycle; 5–7 cc of venous blood were withdrawn to assay serum 
levels of estradiol, progesterone, and testosterone. Knee laxity was measured as the amount of 
anterior tibial displacement at 133 N, using a standard knee arthrometer. To evaluate the 
relationship of knee laxity to changes in sex hormone concentrations, a multiple linear regression 
model with the possibility of a time delay was performed on each individual subject and the  
group as a whole.  
Results: Individual regression equations revealed an average of 63% of the variance in knee 
laxity was explained by the three hormones and their interactions. All three hormones 
significantly contributed to the prediction equation, and the amount of variance explained was 
substantially greater when a time delay was considered. On average, knee laxity changed  
approximately 3, 4, and 4.5 d after changes in estradiol, progesterone, and testosterone, 
respectively. When females were analyzed as a group, only 8% of the variance in knee laxity was 
explained by sex-hormones levels.  
Conclusion: Changes in sex hormones mediate changes in knee laxity across the menstrual 
cycle. However, the strength of this relationship, the relative contribution of each hormone, and 
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the associated time delay are highly variable between women. This individual variability is 
consistent with the variability in menstrual cycle characteristics among women. 
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Article: 
Sex hormones appear to influence the strain behavior (4,9,24) and metabolism (30) of the human 
anterior cruciate ligament (ACL), and the fluctuation in these hormones across the menstrual 
cycle has been implicated as a potential risk factor for ACL injury in females (25,29). Males and 
females differ dramatically both in the type and level of circulating sex hormones. Females are 
also exposed to rhythmic fluctuations in endogenous hormones, with both the absolute levels of 
estrogen and progesterone and their ratio to each other varying considerably during the course of 
the menstrual cycle. Although changes in testosterone levels across the menstrual cycle have 
garnered less attention, this hormone also fluctuates across the menstrual cycle and can vary by 
phase (3,14). 
 
Research suggests that estrogen and progesterone may influence collagen structure and 
metabolism. Estrogen and progesterone receptors have been identified on the human ACL (13), 
and there is evidence to suggest that when the ligament is exposed to increased estrogen levels, 
there is a dose dependent antagonist effect on fibroblast proliferation and procollagen synthesis 
that is attenuated within 3–7 d after administration (30). Although not specific to the human 
ACL, other studies have also noted profound effects of estrogen and progesterone on collagen 
properties in both animal and human models. These effects include both increased collagen 
synthesis and degradation (5,6,8), increased elastin content (23), and decreased total collagen and 
protein content, fiber diameter, and density (1,7) with exposure to estrogen. The interaction of 
estrogen with progesterone appears to enhance these effects, whereas progesterone or 
testosterone alone attenuates these effects (1,7). Collectively, these findings suggest the 
metabolism and structure of collagen tissues may be significantly altered when exposed to 
varying concentrations of sex hormones. 
 
Based on these basic science investigations, research in recent years has examined the influence 
of sex specific hormones on knee joint laxity (anterior knee joint displacement with an anterior 
directed force) via instrumented arthrometry in pregnant (2,21) and normal menstruating females 
(4,9) at a macroscopic level. Using a standard knee arthrometer to apply anterior-directed loads 
of 89 N and 133 N to displace the tibia relative to the femur, significant increases in knee laxity 
during the periovulatory and luteal phases, when compared with menses (i.e., the early follicular 
phase), have been found (4). Similar increases in the periovulatory and luteal phases compared 
with menses, measuring knee laxity and serum estrogen and progesterone levels on days 1, 10–
13, and 20–23 in seven subjects have also been reported (9). Profound but transient increases in 
joint laxity have also been demonstrated during pregnancy (2,21), when levels of estrogen and 
progesterone increased steadily from 6 to 42 wk (27). Although the hormone relaxin is also 
present at higher concentrations during pregnancy, no correlation was found between joint laxity 
and relaxin levels (21). Relaxin levels were highest in the first trimester and decreased in each 
trimester following, whereas knee laxity increased an average of 105%, 128%, and 170% in the 
first, second, and third trimesters, respectively. Although it is appreciated that the hormonal 
milieu is substantially different during pregnancy, these studies lend additional support to a 
relationship between female sex hormones and ligament behavior. 
 
What is yet unclear from these studies is the immediacy and duration of hormonal effects on 
knee joint laxity, or the relative contribution of each hormone to changes in knee joint laxity. 
Studies to date provide only limited ―snap shot‖ measurements of knee laxity at various general 
phases in the menstrual cycle or pregnancy term and have not attempted to relate changes in knee 
laxity to changes in specific hormones. For example, whether findings of increased laxity in the 
luteal phase represents a delayed effect from estrogen surges at ovulation that remained elevated 
into the luteal phase versus an interactive effect between estrogen and progesterone as they rise 
together in the early luteal phase cannot be determined (9). Considering evidence that 
progesterone may enhance estrogen’s effect on reducing collagen content in capsular tissues 
(1,7), and findings that demonstrate greater increases in knee laxity during the third trimester of 
pregnancy when progesterone levels are nine times greater than estrogen (21), it is necessary to 
consider the relative phasing and levels of both hormones. 
 
Moreover, pooling data by phase makes it difficult to determine the relative phasing and timing 
of changes in knee laxity with changes in hormone concentrations. Appreciating that estrogen 
levels can change dramatically within a 24-h period, daily measures, particularly around 
ovulation and the early luteal phase, are desirable. Using particular days of the cycle to estimate 
day of ovulation or cycle phase are likely to be inaccurate and cause considerable variability in 
the data. Studies involving healthy, premenopausal young women have reported regular cycle 
lengths ranging from 21 to 38 d (3,11,15) and the day of ovulation ranging from 10 to 23 d 
(11,19,26). 
 
Also absent from these studies is the examination of endogenous testosterone levels. Although 
females have significantly lower testosterone levels than males, small but significant fluctuations 
in testosterone have been noted across the cycle (3,14). Testosterone levels have also been shown 
to influence the lengths of the follicular and luteal phases of the menstrual cycle (26) and can 
vary in women as a function of obesity (28) and hyperandrogenism (26). Considering that males 
have nearly 10-fold higher levels of serum testosterone, it is plausible that higher absolute or 
transient increases in testosterone levels may confound the potential relationship between 
estrogen, progesterone and knee laxity. 
 
In summary, much is yet unknown about the relationship between changes in sex hormone levels 
across the cycle and corresponding changes in knee joint behavior. In an effort to better 
understand this relationship, our purpose was to comprehensively quantify through daily, serial 
measures changes in knee laxity as a function of daily changes in sex hormone levels across one 
complete menstrual cycle. We hypothesized that 1) changes in knee laxity would occur at an 
identifiable time delay after a rise in hormone levels; 2) estradiol and progesterone combined 
would explain more of the variance in knee laxity than either hormone alone and that 
testosterone levels would have a negligible or negative effect on knee laxity changes; and 3) 
consistent with the variability in individual cycle characteristic between females, the relationship 
between hormone concentrations, and knee laxity would also be variable between women. 
 
METHODS 
Subjects. 
Twenty-five nonathletic female subjects, between the ages of 18 and 30, with a body mass index 
(BMI = weight/height
2
) less than or equal to 30, who reported normal menstrual cycles (28–32 d) 
over the past 6 months were recruited to participate. A sample size of 20 subjects was 
determined a priori though pilot analysis. However, given the daily data collection needs of this 
project, 25 subjects were recruited to offset the potential for subject drop out. Inclusion criteria 
were no history of pregnancy, no use of oral contraceptives or other hormone-stimulating 
medications for 6 months, nonsmoking behavior, two healthy knees with no prior history of joint 
injury or surgery, no medical conditions affecting the connective tissue (e.g., Marfan’s 
Syndrome, Ehlers-Danlos disease, rheumatoid arthritis, etc.), and physical activity limited to 7 h 
or less per week. Participants were excluded from the analyses if they experienced an 
anovulatory cycle or missed three or more consecutive days of testing. An anovulatory cycle was 
determined when the ovulation kit did not test positive or progesterone levels did not rise to 3 
ng·mL
-1
 (10,22). All subjects were informed of the study and associated risks, and signed an 
informed consent approved by the University Health System’s Human Investigation Committee. 
The study also received approval from the University’s General Clinical Research Center’s 
Research Advisory Committee. 
 
Procedures. 
At the beginning of the study, participants were provided with a commercially available 
ovulation kit [CVS One Step Ovulation Predictor (Sensitivity 20 mIU·mL
-1
 LH, accuracy 99%); 
CVS Corporation, Woon-socket, RI] to use beginning on day 8 of their menstrual cycle and were 
asked to report to the research study coordinator the day the test became positive. Day of 
ovulation was confirmed to: 1) ensure a normal, ovulatory menstrual cycle had occurred; 2) to 
provide a common reference point by which to counterbalance participants and to mark the 
beginning and ending of data collection; and 3) to provide indirect confirmation that female 
subjects were not pregnant. 
 
All testing was performed in the University’s General Clinical Research Center. Participants 
were tested daily across one complete menstrual cycle, undergoing the same data collection 
procedures on each day of testing. To control for diurnal fluctuations in hormone levels, testing 
was performed at the same general time of day (8:00 a.m. to 12:00 p.m.) for all subjects.  
Participants were counterbalanced to begin and end data collection either at ovulation (ovulation 
kit detecting the luteinizing hormone (LH) surge), or the onset of menses (self-report of the first 
day of menstrual bleeding). The counterbalance was assigned by an independent investigator to 
blind the test examiner to the participant’s time in the cycle. 
 
Upon arrival each day, participants had 5–7 cc of venous blood withdrawn from which to assay 
serum levels of estradiol (pg·mL
-1
), progesterone (ng·mL
-1
), and testosterone (ng·mL
-1
). Estradiol 
was analyzed using a double-antibody RIA Assay (DSL-4400; Diagnostic Systems Laboratories, 
Webster TX). Progesterone and testosterone levels were analyzed using chemiluminescence 
assays (Coat-A-count; Diagnostic Products Corporation, Los Angeles, CA). Given our desire and 
need to detect day-to-day changes in our data, we ran quality control checks at the front and back 
end of each estradiol assay to determine measurement precision. Mean percent coefficient of 
variations (%CV) were 8.1% for intra-assay (range 3.9–14.1%) and 8.1% for interassay (range 
2.8–16.3%) comparisons. As further confirmation of acceptable measurement repeatability, 
estradiol levels for five participants were analyzed in duplicate for all test days and found to be 
quite consistent (ICC 2,1 = 0.99 for all subjects; SEM = 1.0–1.6). Percent CV for progesterone 
and testosterone were similar, with progesterone ranging from 3.4 to 10.0% for intra-assay and 
3.8 to 12.0% for interassay, whereas testosterone ranged from 4.5 to 11.3% for intra-assay and 
5.2 to 13.8% for interassay. 
 
Knee laxity was defined as the amount of anterior tibial displacement at 133 N, measured by a 
KT 2000
TM
 knee arthrometer (MEDmetric® Corp., San Diego, CA). Subjects were positioned per 
manufacturer’s guidelines in supine with a thigh support placed just proximal to the popliteal 
fossa to support the subject’s knee in 25° of flexion. Their ankles were placed in the 
manufacturer provided foot cradle, and a Velcro strap was placed around the subject’s thighs to 
control rotation of the lower extremity. Once positioned, the KT-2000
TM
 was applied to the 
anterior tibia of the lower extremity (side counterbalanced between participants) in proper 
alignment with the subject’s joint line per manufacturer’s instructions. Participants were 
instructed to relax the leg muscles and an anterior-to-posterior directed force was applied to the 
anterior tibia to identify a stable neutral point from which measures were based. Using consistent 
pressure over the patella stabilizing plate, an anteriorly directed force just over 133 N was then 
applied. A bubble level affixed to the device insured a direct anterior pull was achieved for each 
trial. Five trials were collected on each day of testing, and the average of the middle three trials 
was recorded as the participant’s knee laxity measure. The first trial was used as a ―conditioning‖ 
trial and a fifth trial was collected and used only in the rare event of a device malfunction or loss 
of data of one of the middle three trials. Although we also obtained displacement values at 46 N 
and 90 N, preliminary graphical and statistical comparisons of knee laxity changes between these 
measures and 133 N confirmed cyclical changes were not force dependent. Hence, laxity at 133 
N was chosen as the criterion variable for this study, as this measure is most commonly reported 
clinically and in the literature, allowing closer comparisons to previous works. 
 
A single investigator performed the majority of knee laxity measures throughout the study. 
However, because of the daily data collection demands of this study, and the restriction of testing 
to the morning hours, a second investigator was also trained to perform knee laxity measures 
when the primary tester was unavailable. Except for isolated cases, the second tester was used 
primarily during the course of one academic semester, due to a schedule conflict 2 d a week for 
the primary tester. Hence, data on the last 17 subjects were obtained by two investigators, with 
the second tester collecting data on Tuesdays and Thursdays. To limit the effects of measurement 
variation between testers, both testers participated in extensive pilot testing before actual data 
collection to establish acceptable intertester and intrat-ester reliability. After a 2-wk period of 
practice and training, each tester completed two sets of five trials on two separate days, with the 
participant removed and repositioned for each test set (counterbalanced). The mean of the middle 
three trials obtained from each tester and test day were used for data analysis. Mean absolute 
knee laxity values at 133 N for day 1 versus day 2 were 4.36 ± 1.72 versus 4.42 ± 1.64 mm 
(tester 1) and 5.01 ± 1.61 versus 5.10 ± 2.07 mm (tester 2). Reliability estimates were calculated 
using Interclass correlation formula 2,k (ICC (2,k)) and the SEM. Results revealed the measures 
obtained at 133 N were quite consistent both within [ICC (2,k) = 0.97, SEM = 0.38 (T1); ICC 
(2,k) = 0.95, SEM = 0.38 mm (T2)] and between (ICC (2,k) = 0.92, SEM = 0.50) the primary 
and secondary testers (17). These data also support our ability to detect changes in knee laxity of 
0.08–1.0 mm (95% confidence interval) within subjects as a function of changes in hormone 
levels. 
 
Data analysis. 
Data on hormone concentrations (estradiol, progesterone, testosterone) and anterior knee laxity 
at 133 N were recorded for each testing day. To examine the relationship between changes in 
knee laxity to changes in hormone concentrations, a series of multiple linear regression models 
using hormone concentrations as the predictor variables and knee laxity as the criterion variable 
were performed. To test the hypothesis that changes in knee laxity do not occur immediately, but 
at an identifiable time delay after a change in hormone concentrations, the multiple linear 
regression model was computed over a series of time shifts ranging from 0 to 8 d. The complete 
equation for this model (i.e., including all variables and interactions), using knee laxity as the 
criterion measure of interest, was as follows: 
 
Equation U1 
 
where each of the hormones was a function of a time shift (t-[DELTA]t) relative to knee laxity, 
and A-H represented the constants for each variable. By allowing the hormone data to shift 
forward 0–8 d relative to the knee laxity values obtained on the same day, we identified any time 
delay (± its SE) in changes in knee laxity relative to the change in estradiol, progesterone, and 
testosterone levels. Therefore, this model allowed us to both compare the magnitude of the 
relationship between sex hormones and knee laxity across multiple time delays, and to quantify 
the magnitude of the time delay at which this relationship was the strongest. To accommodate 
these time shifts, data for each subject were repeated end to end three times. This prevented us 
from losing any data points at the beginning (hormone concentration values) or end (laxity 
values) of the cycle once the data were shifted and insured that the regression equation computed 
for each time shift was based on equivalent data sets. 
 
To test the hypotheses that estradiol and progesterone combined with their interactions would 
explain more of the variance in knee laxity changes than either hormone alone and that 
testosterone levels would have a negligible or negative effect on knee laxity changes, we 
compared simpler models that included: 1) only the main effects for estradiol and 2) only the 
main effects of estradiol, progesterone, and testosterone with the full regression model 
previously noted. These models were compared with and without the possibility of a time shift. 
The inclusion of each hormone is based on the assumption that they are somewhat independent 
of one another in their mechanisms and actions on connective tissue (1,7) and will each provide 
unique contributions to the total variance explained. 
 
To determine whether the relationship between hormone concentrations and knee laxity is 
sufficiently variable between women to warrant individual subject analyses, we compared the 
results of the individual regression analyses with a group regression analysis that was performed 
in the same fashion as the individual models but with all subjects entered simultaneously. To 
allow us to focus primarily on the relationship between the relative changes in each variable 
across the menstrual cycle, the mean values for each variable was subtracted from each data 
point within each subject before being entered in the analyses. 
 
RESULTS 
Three participants were excluded from the study, one due to voluntary withdrawal, one to an 
anovulatory cycle, and one due to equipment failure that resulted in more than three consecutive 
days of missed data collection. Subject demographics for the 22 participants included in the 
analyses are provided in Table 1. Study compliance for these subjects was excellent, with 15 
subjects completing all days of data collection and 7 missing one (N = 6) or two (N = 1) days of 
data collection. 
 
TABLE 1. Group demographics. 
Time delay between changes in hormone levels and knee laxity. 
Table 2 shows the variance in knee laxity explained by the hormones was substantially greater in 
the regression model where a time shift was allowed compared with the model with no time 
shift, suggesting that any changes in knee laxity in response to changes in serum hormone levels 
are not immediate, but occur a few days later. Table 3 lists the time shifts (days) that explained 
the greatest amount of the variance in knee laxity across the cycle for each individual subject and 
the group as a whole, based on data from the full regression model. The average phase shifts 
were ~3 d for estradiol, 4 d for progesterone and 4.5 d for testosterone. However, as noted in the 
table, the range of phase shifts was quite variable between subjects, as was the phase shifts 
between each hormone within each subject. Figure 1 graphically depicts this time shift in one 
subject. 
 
TABLE 2. Comparison of % variance explained (R
2
) between simple and more complex regression models. 
 
 
TABLE 3. Time delays for individual and group (N = 22) regression models explaining the greatest amount of 
variance in knee laxity changes across the menstrual cycle. 
 
 
FIGURE 1—Graphic representation of subject 26, showing a characteristic time delay between change in hormone 
levels and change in knee joint laxity. 
 
Relationship between hormone concentrations and knee laxity. 
Our second hypothesis was that estradiol and progesterone combined would explain more of the 
variance in knee laxity changes than either hormone alone, with testosterone having a negligible 
or inhibitory effect on knee laxity changes. Table 2 also shows the comparison of variance 
explained in the primary model compared with each of the simpler models with and without time 
shifts. Although we intended to explore the role of testosterone and its potential interaction with 
estradiol and progesterone as a secondary interest, these comparisons revealed that the inclusion 
of testosterone in the analysis substantially contributed to the variance explained in the data. 
Given our findings in support of hypotheses 1 and 2, the full regression model with the potential 
for a time delay was used to determine the relationship between changes in hormone 
concentrations and changes in knee laxity. 
 
Two primary relational trends were noted in the full regression model, with nine subjects 
showing one trend and eight subjects showing an opposite trend (Table 4). Subjects 6, 9, 17, 21–
25, 27, 33, and 38 predicted knee laxity with the individual hormone coefficients being positive, 
the two-way interaction coefficients negative, and the three-way interaction coefficient positive. 
Subjects 8, 15, 16, 20, 34, 35, 36, and 37 predicted knee laxity, with the relationships being 
exactly opposite. 
 
 
TABLE 4. Individual and group regression coefficients and variance explained in knee laxity by changes in 
estradiol, progesterone, and testosterone across the menstrual cycle. 
 
Of those showing the second trend, unusually large constants (mean laxity values) were observed 
that suggests a poor regression fit (i.e., the resultant constant was substantially different than the 
actual mean laxity values for that subject). We then recomputed the regression equation with the 
constant removed (i.e., essentially subtracting the mean laxity value from each data point), 
making the intercept ―0‖ for all subjects and focusing only on the value of change from day to 
day. Table 5 lists the phase shifts and regression coefficients explaining the greatest amount of 
variance with the constant removed. These results revealed 18 of 22 subjects yielding equations 
consistent with the trend of individual hormone coefficients being positive, the two-way 
interaction coefficients negative and the three-way interaction coefficient positive. To confirm 
the accuracy of the prediction equation and whether removing the constant truly yielded a better 
fit to the actual data, Figure 2, a and b, compares the prediction equations with and without the 
constant included for one subject (subject 15) who initially showed a relationship consistent with 
the opposite trend. Removing the constant (Fig. 2b) clearly yielded a better fit to the 
corresponding raw data. 
 
TABLE 5. Individual and group (N = 22) regression model coefficients and phase shifts with constant removed. 
 
 
FIGURE 2—Graphic representation comparing fit of prediction equation to actual raw data collected for subject 15. 
Figure A compares raw data to prediction equation with constant. Figure B compares raw data to prediction equation 
with constant = 0. 
 
Comparison of individual versus group results. 
Examination of the group regression analyses revealed that when data for all subjects were 
pooled, only ~8% of the variance in knee laxity was explained by the three hormones (see group 
data, last rows of Tables 4 and 5). The corresponding time shifts for the pooled data were 3 d for 
both estradiol and progesterone and 8 d for testosterone. Although the interaction of estradiol and 
testosterone was a significant predictor of knee laxity in the group model, the interaction of 
estradiol with progesterone, and progesterone with testosterone contributed little to the 
regression model. 
 
DISCUSSION 
The primary findings were that estradiol, progesterone, and testosterone each contribute to 
changes in knee laxity across the cycle, and that this relationship is stronger when changes in 
hormone concentrations are compared with changes in knee laxity occurring approximately 3–4 
d later. However, the variable time shifts between subjects and the substantially greater variance 
explained by the regression model for each individual subject compared with the group analysis 
suggests this relationship is quite variable between subjects. 
 
Relationship between hormone concentrations and knee laxity. 
Our findings support our hypothesis that estradiol and progesterone combined would explain 
more of the variance in knee laxity changes than either hormone alone but appear to reject our 
hypothesis that testosterone would have a negligible or negative effect on knee laxity changes. 
Considerably more variance in knee laxity was explained when all three hormones and their 
interaction were included in the model. As the multiple regression analysis is able to account for 
any correlations that exist between the hormones, these findings would support our assumption 
that each hormone contributes unique information to the total variance explained in knee laxity. 
Two primary and opposing trends were revealed in the full regression model when the constant 
(mean laxity value) remained in the equation. We believe this is likely due to the absolute 
magnitude of the interactive terms (due to high concentration levels of one or both hormones) 
that in some cases potentially suppressed the contribution of the individual hormone, yielding an 
inaccurate prediction equation. This seemed to be corrected once the mean laxity value was 
removed from the data, forcing the regression model to explain all of the variance in the data. 
Once the constant was removed, a rather consistent regression model was noted. From these 
data, it can be seen that, in the majority of cases, knee laxity increases were associated with 
isolated increases in estradiol, progesterone, and testosterone and with increased concentrations 
of all three hormones together. Knee laxity decreased when the cross product of estradiol and 
progesterone, estradiol and testosterone, and progesterone and testosterone increased. However, 
it is important to note that the value of each regression coefficient is dependent on which other 
independent variables are in the equation. Hence, the described changes in knee laxity with each 
of these variables are relative to one another and should not be considered in isolation. 
 
In all cases, both across individual subjects and the group comparison, estradiol, testosterone, 
and the interaction of estradiol and testosterone were significant predictors in the regression 
equation (Table 4). Coefficients that included progesterone or its interaction contributed less to 
the variance explained and were not always significant predictors in the equation. The amount of 
variance explained by progesterone alone (Table 2) or the relative magnitude of changes in 
progesterone across the cycle did not appear to be factors in the strength of this relationship. Our 
findings are consistent with basic science studies comparing progesterone effects on collagen 
content, density, and elastin content. Progesterone alone was found to have a lesser effect on 
collagen tissue than either estrogen or testosterone alone (23), with its effect being either positive 
or negative depending on whether it was administered in combination with estrogen (1,7). 
Hence, the degree of synchrony between the rise and fall of estrogen and progesterone during the 
luteal phase may dictate whether the contribution of progesterone has a negative vs positive 
relationship with changes in knee laxity. Our findings from simpler regression models support 
this, as increases in knee laxity were always associated with increases in estradiol and 
testosterone, but could either increase or decrease with progesterone levels, depending on the 
subject. 
 
A unique finding of this study was the significant contribution of testosterone in predicting knee 
laxity changes. Studies published to date have only examined changes in knee laxity across the 
cycle where relative and absolute levels of estrogen and progesterone are expected to change. 
Although small but significant changes in testosterone levels have been noted across the cycle 
(3,14), our original intent was to include testosterone simply as a control variable. Appreciating 
that some women are known to have significantly higher testosterone levels in response to 
certain physiological characteristics (26,28), we felt this could possibly suppress the effect of 
estradiol and progesterone and confound our findings. In reality, testosterone had a positive 
rather than negative relationship with changes in knee laxity, essentially augmenting the 
relationship. In fact, testosterone, on average, explained more of the variance in knee laxity than 
progesterone (Table 2). 
 
One must be cautious however not to view this relationship as one of cause and effect. If 
testosterone were to be a true agonist increasing knee laxity, one would expect males (who have 
significantly higher concentrations of testosterone) to have greater knee laxity than females. 
However, research has shown this is not the case (18,20). Whether the strength of the 
relationship between testosterone and knee laxity is dose dependent or is influenced by the 
relative presence of other hormones is unclear and requires further study. Although previous 
reports indicate an interactive effect of these competing sex hormones when present together 
(1,7,23), these investigations did not specifically evaluate the interaction of estradiol and 
testosterone in combination. Finally, as estradiol is metabolized to testosterone in peripheral 
tissues via the enzyme aromatase (16), it is difficult to completely separate the two hormones. 
However, data from the regression model suggest that they are at least somewhat independent in 
their actions, as they each contributed significantly to the model once their co-linearity had been 
accounted for. Further study is needed to clarify the interactive and dose dependent effect of 
testosterone as well as that of progesterone on knee laxity. 
 
Time delay between changes in hormone levels and knee laxity. 
Our findings support our hypothesis that the relationship between sex hormones and knee laxity 
is stronger when a time delay is considered. Although the average time delay was 3–4 d, the 
actual time delay was quite variable between the females in this study (Table 3). Qualitative 
inspection of the data failed to reveal any readily apparent observations to explain the individual 
variability in the time delay between the rise and fall of the three hormones and knee laxity. 
Because of the number of variables that are changing at any one time in the cycle, it was difficult 
to identify any one factor or group of factors that might explain this variability. However, we 
suspected that the relative change in concentration levels across the cycle, as well as the timing 
of change in one hormone relative to another, were likely factors contributing to these variations. 
Hence, we followed this qualitative assessment with an exploratory post hoc multivariate linear 
regression, and found that 75% of the variance in the estradiol phase shift was explained by the 
length of the follicular phase and the absolute levels of estradiol and progesterone. Essentially, 
the time delay between changes in estradiol levels and changes in knee laxity was greater 
(identified by an increasing positive shift in Table 3) in subjects who had a longer follicular 
phase, higher mean levels of estradiol and progesterone, and lower peak estradiol levels. In other 
words, knee laxity was slower to respond when there were less dramatic changes in estradiol 
levels. This would seem reasonable given the positive relationship between estradiol and knee 
laxity in the individual regression models. 
 
Although these observations are exploratory in nature and are presented for descriptive purposes 
only, they once again suggest that multiple factors contribute to this variable relationship 
between women and the need for further inquiry in this area. These findings also reinforce the 
limitation of using a specific day or range of days (e.g., days 10–14 for ovulation, days 14–28 for 
luteal phase) to represent the same time point or ―phase‖ in the cycle for all women. We suggest 
a more accurate way to compare physiological changes across menstrual cycle phases in future 
studies is to use a time-dependent factor relative to when a particular hormone rises and falls. 
 
Intersubject variability. 
Comparison of the individual and group regression model supports our third hypothesis, that the 
relationship between hormone concentrations and knee laxity is quite variable between women. 
Consistent with previous literature (11), females in this study varied considerably in the length of 
their cycle (both follicular and luteal phases), as well as the hormone phasing and absolute 
changes in hormone levels across their cycle (Table 1). Given this variability, it is not surprising 
that the range of phase shifts and regression coefficients corresponding to each subject were also 
variable (Tables 3–5). We were surprised to find, however, the variable contribution of each 
hormone to changes in knee laxity. In some cases the variance in knee laxity explained by the 
three hormones was fairly equal, whereas in other cases a single hormone would predominate 
(Table 2). Still other cases showed very weak relationships between knee laxity and all three 
hormones, until the interactions of these hormones were also considered. These findings once 
again demonstrate the considerable variability among women and the complex relationship that 
exists between sex hormones and changes in knee joint laxity. 
 
Another important clinical finding of this study is that not all women demonstrated the same 
degree of knee laxity change across the cycle. Whereas some subjects had a 4- to 5-mm increase 
in knee laxity across the cycle, other subjects showed little or no change. We believe this 
intersubject variance is again due to the individual variability in menstrual cycle characteristics, 
relative to both the concentration and timing of circulating sex hormones as well as the 
variability of each individual’s response to sex hormone concentrations. Should sex hormones 
ultimately be linked to anterior cruciate ligament injury risk, these findings suggest this may 
represent a variable risk factor among women. 
 
Clinical relevance. 
Our findings support the influence of sex hormones on biomechanical properties affecting knee 
joint laxity. Sufficient evidence now exists that women generally have greater knee joint laxity 
than males (18,20) and that transient increases in knee laxity occur in women across the 
menstrual cycle as a function of changing hormone levels. When considering the results of the 
regression model, our findings would suggest that the continued increase in knee laxity from the 
periovulatory to luteal phase of the menstrual cycle found in previous studies (4,9) may be more 
a function of a delayed response to the initial estradiol rise than an interactive effect with 
progesterone. Hence, future studies should consider less important the hormonal environment at 
the time of measurement or injury but rather focus more so on the hormonal milieu during the 
preceding 4–7 d. 
 
What remains unknown is the consequence of these transient increases in knee laxity on 
neuromuscular and biomechanical function of the knee and subsequent injury risk. Given the 
biological and morphological changes in collagen that have been previously described (1,7,30), 
increased knee laxity may represent a substantial alteration of the mechanical properties of the 
ACL when exposed to large fluctuations in hormone levels, rendering the collagen tissue more 
compliant and susceptible to tensile failure and injury. This is supported by work that has found 
estrogen to alter the failure load of the ACL (24) and that ACL injury risk may be cycle 
dependent (25,29). 
 
To elucidate the contribution of sex hormones and knee laxity to ACL injury risk, future studies 
should begin to explore the consequence of hormone-mediated changes in knee laxity on 
neuromuscular and biomechanical function of the lower extremity. Unfortunately, the 
considerable intersubject variability in the relationship between sex hormones and knee laxity 
presents substantial challenges to exploring this consequence. The variable contribution of each 
hormone as well as the variable time shifts associated with these hormones makes it difficult to 
predict with certainty when knee laxity will be at its minimum and maximum across the 
menstrual cycle. Although knee laxity generally increases in the postovulatory/early luteal phase 
of the menstrual cycle, this increase can be rather transient and short lived. Moreover, we often 
observed a second transient increase in knee laxity near the end of the luteal phase and start of 
menses, presumably a delayed response to the second rise in estradiol levels in the midluteal 
phase (see Figs. 1 and 2). As knee laxity appears to transition both in the postovulatory and late 
luteal phases of the cycle, this may explain in part what some may consider contradictory 
findings of increased injury risk in both the periovulatory (29) and early menstrual (25) phases of 
the cycle. Future investigators should consider expanding their range of time measurements to 
capture the end of the cycle characteristics as well. 
 
Limitations. 
Collecting data on a daily basis across one complete menstrual cycle is not without challenges. 
The potential for subject attrition, missed days due to illness and holiday, and equipment failure 
in the course of the study is not trivial. Even with these challenges, we were able to obtain near 
complete data on over 85% of our subjects. Although the information gained from these subjects 
has yielded considerable insight regarding the relationship between changes in hormone levels 
and knee joint behavior, it is not without limitations. An unavoidable limitation in a study of this 
magnitude was the need for two testers to obtain laxity measures, which may introduce more 
measurement error than a single tester. Although we made every effort to extensively train both 
testers and confirm acceptable intra- and intertester reliability, some variance between testers 
was noted. Ideally, we would have had one tester collect all measurements on a single subject, 
but the daily data collection needs of this project essentially made this impossible. Although this 
may have introduced greater error variance in the data, the fact that consistent trends were noted 
in our findings suggests this concern may be minimal. 
 
A second acknowledged limitation to this study is the end-to-end data procedure used in our 
analyses to accommodate the phase shifts. Had we not performed this procedure, we would have 
essentially lost the knee laxity data for the first 8 d of the cycle (i.e., menses) once the hormone 
data was shifted. However, placing each subject’s data set end-to-end assumes that the preceding 
and following menstrual cycles are consistent, and may have reduced the accuracy of the 
prediction equation, particularly in regard to the time delay characteristics. Although cycle 
variability is substantially less within women than between women (12), cycle-to-cycle 
variations do exist. The only way to have truly determined cycle length would have been to 
measure daily samples for 3 months (before, during, and after), which would have been 
prohibitive, both in terms of inconvenience to the subjects and cost. Future studies wishing to 
replicate these findings should collect data for a sufficient number of days preceding and 
following the cycle of interest to accommodate the desired range of time shifts. However, the 
need to collect additional days of data poses further challenges to confining data collection to a 
single tester. 
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